Evidence map›Paper›PMID 20863855›Full record

ArticleJournal of virological methods2010

Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.

Peilin Li, Theodore Ruel, Katsuya Fujimoto, Hiroyu Hatano, Steven Yukl, Leigh Anne Eller, Teri Liegler, Moses Kamya, Anne Gassasira, Grant Dorsey and 3 more

Abstract read
In one paragraph

Article in Journal of virological methods, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. How CD4Biomedicines · 2023
    Article
  2. Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Peilin LiUniversity of California, San Francisco (UCSF), Department of Medicine, San Francisco, CA 94121, USA. Peilin.li@va.gov
Theodore Ruel
Katsuya Fujimoto
Hiroyu Hatano
Steven Yukl
Leigh Anne Eller
Teri Liegler
Moses Kamya
Anne Gassasira
Grant Dorsey
Philip J Rosenthal
Diane V Havlir
Joseph K Wong
University of California, San Francisco · USMakerere University · UGSan Francisco General Hospital · US

Funding

San Francisco Vaccine and Prevention UnitUM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · PI Susan Buchbinder, Diane V Havlir · 2012 to 2026
$30.5M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
HIV-1 Adaptation in the Central Nervous SystemR01NS051132 · NINDS · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WONG, JOSEPH K · 2005 to 2009
$1.8M
Therapeutic Strategies for HIV DiseaseK24AI051982 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2002 to 2012
$1.3M
HIV Disease Progression in African ChildrenK23HD060459 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI RUEL, THEODORE DUMONT · 2010 to 2014
$627k
Variation in Neurocognitive Impairment of HIV Ugandan Children by HIV SubtypeR21MH083573 · NIMH · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI WONG, JOSEPH K · 2008 to 2009
$407k
Quantification of HIV-1 Reservoirs in the GutK23AI089397 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YUKL, STEVEN A · 2010 to 2010
$125k
NIAID NIH HHS K23 AI089397NIAID NIH HHS K24 AI051982NIAID NIH HHS T32 AI060530NIAID NIH HHS T32 AI60530NIAID NIH HHS UM1 AI069496NICHD NIH HHS K23 HD060459NIMH NIH HHS R21 MH083573NINDS NIH HHS R01 NS051132NINDS NIH HHS R01 NS051145
6 · The paper itself

Abstract

There remains a need for sensitive and cost-effective assays to monitor therapy in human immunodeficiency virus type-1 (HIV-1) infection. However, the genetic diversity of HIV poses difficulties for traditional real-time PCR assays that require long oligonucleotides probes. LNA™ probes may be useful in overcoming these limits to traditional probe design. A new application of LNA™ chemistry in a Taqman assay applicable to a wide range of HIV-1 subtypes is described. This assay, based on a 13-mer LNA™ probe that matches the majority of HIV-1 sequences in the Los Alamos database, exhibited a wide dynamic range (10(1)-10(7) copies of HIV DNA), high sensitivity (limit of detection of 1 copy of HIV DNA in 10(5) cells), and broad applicability to a range of HIV-1 subtypes (including A, B, C, D, F, H, B/C, and A/E CRFs). Using the LNA™ probe assay, HIV-1 DNA was detected in all dried blood spots (DBS) from treatment naïve HIV-1 positive Ugandan children, and HIV DNA levels significantly correlated with viral RNA levels in plasma (r=0.765, p<0.0001). This approach to Taqman probe design should be explored further for use in diagnosis and monitoring of HIV in resource-limited settings, especially where several subtypes co-circulate.

Indexed as

ChildDNA, ViralGenetic HeterogeneityHIV-1HIV InfectionsHumansOligonucleotidesPolymerase Chain ReactionReagent Kits, DiagnosticRNA, ViralSensitivity and SpecificityUgandaDNA, Virallocked nucleic acidOligonucleotidesReagent Kits, DiagnosticRNA, Viral

Identifiers

PMID20863855
PMCPMC3280821
OpenAlexW2023723974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.